alphaveGLENMARK₹2,403.10

Glenmark Pharmaceuticals Ltd.

Annual Quarterly₹ CrorePeersDRREDDY LUPIN ALKEM BIOCON MANKIND LAURUSLABS FORTIS AUROPHARMAMcap ₹67,815 Cr

View

In ₹ Crore except Per Share 12 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	3,207.4	2,506.7	3,063.0	3,244.2	3,433.8	3,387.6	3,256.2	3,264.4	6,046.9	3,900.6	3,770.6	4,018.5
Other Income	1.7	45.4	773.2	31.5	39.4	31.1	11.7	26.4	200.6	44.5	189.1	65.8
Total Income	3,209.1	2,552.1	3,836.1	3,275.7	3,473.2	3,418.7	3,267.9	3,290.9	6,247.5	3,945.1	3,959.7	4,084.2
Expenses
+ Cost of Materials Consumed	915.8	657.5	754.3	685.8	774.4	746.4	794.8	732.5	722.5	775.3	731.2	601.1
+ Purchases of Stock-in-Trade	408.8	413.1	210.8	360.0	443.1	418.2	344.7	581.3	620.4	748.6	446.3	660.8
+ Changes in Inventories	-126.8	-38.4	30.4	64.3	-147.4	-80.3	-50.6	-298.2	-78.4	-228.8	-5.2	-16.0
+ Employee Benefit Expense	732.9	753.0	701.0	710.4	786.6	788.5	736.6	762.8	1,086.3	841.4	887.4	934.7
+ Finance Costs	121.5	134.3	148.6	39.6	48.5	52.3	66.7	58.2	66.5	41.4	42.6	54.0
+ Depreciation & Amortisation	141.5	147.1	151.3	117.8	120.3	122.7	125.2	129.9	141.2	154.4	147.9	173.2
+ Other Expenses	814.4	930.1	862.1	835.5	975.2	914.6	869.7	905.6	1,336.6	894.4	948.3	1,033.2
Total Expenses	3,008.0	2,996.8	2,858.5	2,813.3	3,000.6	2,962.4	2,887.1	2,872.1	3,895.0	3,226.7	3,198.5	3,440.9
EBITDA	462.3	-208.6	504.3	588.2	601.9	600.2	561.0	580.5	2,359.6	869.7	762.6	804.8
EBIT	320.8	-355.7	353.0	470.4	481.6	477.5	435.8	450.6	2,218.4	715.3	614.7	631.6
Profit
PBT before Exceptional Items	201.1	-444.7	977.6	462.3	472.6	456.3	380.8	418.8	2,352.5	718.3	761.2	643.4
+ Exceptional Items	-325.4	-76.7	-446.8	0.0	0.0	0.0	-372.8	-323.2	-1,385.1	-184.3	-373.4	0.0
Pretax Income	-124.4	-521.4	530.8	462.3	472.6	456.3	8.0	95.6	967.4	534.0	387.8	643.4
+ Current Tax	22.7	-22.1	1,058.2	146.9	135.9	103.1	-3.5	109.3	460.0	137.3	-30.1	210.8
+ Deferred Tax	33.2	-49.7	711.3	-24.8	-17.8	5.2	7.1	-60.7	-103.1	-6.5	116.6	-50.3
Tax Expense	55.9	-71.8	1,769.5	122.1	118.1	108.3	3.6	48.6	357.0	130.8	86.4	160.6
Net Income	-63.6	-330.8	-1,214.3	340.2	354.5	348.0	4.4	47.0	610.4	403.2	301.3	482.8
+ Net Income — Continuing Ops	-180.3	-449.6	-1,238.6	340.2	354.5	348.0	4.4	47.0	610.4	403.2	301.3	482.8
+ Net Income — Discontinued Ops	116.7	118.8	24.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	-88.0	4.7	75.9	5.5	-22.4	-176.5	257.6	101.3	104.5	20.0	188.6	40.4
Total Comprehensive Income	-151.6	-326.1	-1,138.4	345.7	332.1	171.6	262.0	148.3	714.9	423.2	489.9	523.3
Net Income to Common	-81.9	-351.4	-1,218.3	—	0.0	0.0	4.7	46.9	610.4	403.2	-0.1	482.9
Minority Interest	20.4	20.6	4.0	—	0.0	0.0	-0.3	0.1	0.1	0.0	301.4	-0.1
Per Share
Basic EPS	-2.90	-12.45	-43.18	12.06	12.55	12.33	0.16	1.66	21.63	14.29	10.68	17.11
Diluted EPS	-2.90	-12.45	-43.18	12.06	12.55	12.33	0.16	1.66	21.62	14.28	10.68	17.11
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	156.9	160.7	31.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Tax — Discontinued Operations	40.2	41.9	6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	257.6	101.3	104.5	20.0	188.6	40.4
+ Items NOT to be Reclassified to P&L	-7.2	-3.5	-9.4	-0.7	-4.5	-0.5	-6.2	0.9	-18.3	3.4	4.6	0.7
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-2.0	0.2	-2.5	1.1	3.6	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-3.0	0.8	-2.7	-0.3	-1.4	-0.2	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-76.2	8.1	84.7	6.1	-16.3	-163.9	261.0	101.8	141.9	24.9	214.7	45.0
+ Tax on Items to be Reclassified	—	—	—	—	—	—	-0.9	1.1	21.6	7.3	27.1	5.1
+ Tax on Items to be Reclassified — alt tag	7.5	-0.9	2.0	0.1	2.9	12.2	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	-288.4	-346.0	-1,142.4	0.0	331.8	171.5	262.2	148.2	714.8	423.2	-0.1	523.4
Comprehensive Income — Non-controlling Interests	20.0	19.9	4.0	0.0	0.2	0.1	-0.3	0.1	0.1	0.0	490.0	-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	-7.11	-16.66	-44.04	12.06	12.55	12.33	0.16	1.66	21.63	14.29	10.68	17.11
Diluted EPS — Continuing Operations	-7.11	-16.66	-44.04	12.06	12.55	12.33	0.16	1.66	21.62	14.28	10.68	17.11
Basic EPS — Discontinued Operations	4.21	4.21	0.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	4.21	4.21	0.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,009.6	1,474.4	2,067.4	2,134.1	2,363.7	2,303.3	2,167.3	2,248.9	4,782.4	2,605.5	2,598.3	2,772.7
Gross Margin %	62.66	58.82	67.50	65.78	68.84	67.99	66.56	68.89	79.09	66.80	68.91	69.00
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	201.1	-444.7	977.6	462.3	472.6	456.3	380.8	418.8	2,352.5	718.3	761.2	643.4
− Exceptional Items (reconciliation)	-325.4	-76.7	-446.8	0.0	0.0	0.0	-372.8	-323.2	-1,385.1	-184.3	-373.4	0.0
Net Income Adj (tax-effected)	261.9	-264.7	-1,035.6	340.2	354.5	348.0	209.4	205.8	1,484.4	542.4	591.5	482.8
EPS Adj	11.95	-9.96	-36.82	12.06	12.55	12.33	7.64	7.27	52.60	19.22	20.96	17.11
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2	28.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.